Fosun Tweaks Gland Deal Amid Limbo In India
Executive Summary
China’s Fosun group isn’t backing off from its $1bn-plus buyout of Gland Pharma and will now pursue a tweaked version of the original deal that technically qualifies for automatic approval under Indian rules. Whether that means smooth sailing hereon remains unclear.
You may also be interested in...
India-China Tango: Can Gland Sustain Listing Luster?
Gland Pharma, controlled by Chinese group Fosun, makes shining debut on Indian stock markets despite a lukewarm response to its IPO. Will the buoyant market sentiment sustain amid edgy India-China relations?
With Eye On China, India Tightens Foreign Investment Vetting
India revises foreign direct investment rules to bridle any attempts at opportunistic M&A amid the COVID-19 crisis. The move is seen largely targeted at China, though pharma experts have mixed views on the new screening measures.
Steady M&A Flow Lifts Fosun
Continuing with its dual strategy driven by innovation and internationalization, Fosun Pharmaceutical recently announced two acquisitions on the trot. The deals separately tap into growth opportunities in new biologic products and build on Fosun’s presence in Africa.